Shanghai Yizhong Pharmaceutical Co Ltd (688091) - Total Assets
Based on the latest financial reports, Shanghai Yizhong Pharmaceutical Co Ltd (688091) holds total assets worth CN¥1.54 Billion CNY (≈ $225.89 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Shanghai Yizhong Pharmaceutical Co Ltd - Total Assets Trend (2017–2024)
This chart illustrates how Shanghai Yizhong Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. Also see 688091 stock market capitalisation for the company's overall valuation and market capitalisation.
Shanghai Yizhong Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Shanghai Yizhong Pharmaceutical Co Ltd's total assets of CN¥1.54 Billion consist of 53.6% current assets and 46.4% non-current assets. Review Shanghai Yizhong Pharmaceutical Co Ltd balance sheet liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 44.5% |
| Accounts Receivable | CN¥54.45 Million | 3.8% |
| Inventory | CN¥45.17 Million | 3.1% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥8.36 Million | 0.6% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Shanghai Yizhong Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See today's stock price for Shanghai Yizhong Pharmaceutical Co Ltd for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shanghai Yizhong Pharmaceutical Co Ltd's current assets represent 53.6% of total assets in 2024, an increase from 48.3% in 2017.
- Cash Position: Cash and equivalents constituted 44.5% of total assets in 2024, up from 1.3% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 4.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 3.8% of total assets.
Shanghai Yizhong Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Shanghai Yizhong Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Torrent Pharmaceuticals Limited
NSE:TORNTPHARM
|
India | Rs443.12 Billion |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Beijing Tongrentang Co Ltd
SHG:600085
|
China | CN¥29.95 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
|
Harbin Pharmaceutical Group Co Ltd
SHG:600664
|
China | CN¥14.08 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
Shanghai Yizhong Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.67 | 18.01 | 24.15 |
| Quick Ratio | 7.84 | 17.37 | 23.84 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥610.92 Million | CN¥798.86 Million | CN¥125.34 Million |
Shanghai Yizhong Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Shanghai Yizhong Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.43 |
| Latest Market Cap to Assets Ratio | 0.87 |
| Asset Growth Rate (YoY) | -8.0% |
| Total Assets | CN¥1.45 Billion |
| Market Capitalization | $1.25 Billion USD |
Valuation Analysis
Near Book Valuation: The market values Shanghai Yizhong Pharmaceutical Co Ltd's assets close to their book value (0.87x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: Shanghai Yizhong Pharmaceutical Co Ltd's assets decreased by 8.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Shanghai Yizhong Pharmaceutical Co Ltd (2017–2024)
The table below shows the annual total assets of Shanghai Yizhong Pharmaceutical Co Ltd from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.45 Billion ≈ $211.89 Million |
-7.97% |
| 2023-12-31 | CN¥1.57 Billion ≈ $230.23 Million |
+16.15% |
| 2022-12-31 | CN¥1.35 Billion ≈ $198.22 Million |
+12.83% |
| 2021-12-31 | CN¥1.20 Billion ≈ $175.68 Million |
+363.88% |
| 2020-12-31 | CN¥258.81 Million ≈ $37.87 Million |
-6.77% |
| 2019-12-31 | CN¥277.62 Million ≈ $40.62 Million |
+21.06% |
| 2018-12-31 | CN¥229.33 Million ≈ $33.56 Million |
+7.29% |
| 2017-12-31 | CN¥213.74 Million ≈ $31.28 Million |
-- |
About Shanghai Yizhong Pharmaceutical Co Ltd
Shanghai Yizhong Pharmaceutical Co., Ltd. engages in the development of anti-tumor drugs and related products in China. It also offers paclitaxel polymer nanomicelles for the treatment of non-small cell lung cancer, as well as various types of cancer, including esophageal cancer, gastric cancer, nasopharyngeal carcinoma, pancreatic cancer, breast cancer, gynecological tumors, etc. The company was… Read more